October 27, 2011

Pacific Biosciences Appoints Michael W. Hunkapiller as Executive Chairman

MENLO PARK, Calif.–(BUSINESS WIRE)–

Pacific Biosciences of California, Inc. (NASDAQ:PACB), provider of

Single Molecule Real Time (SMRT®) sequencing products, today

announced the appointment of Michael W. Hunkapiller, Ph.D., as Executive

Chairman of its Board of Directors. Dr. Hunkapiller, a General Partner

at Alloy Ventures and former President and General Manager of Applied

Biosystems (now part of Life Technologies, NASDAQ: LIFE), has been a

member of the PacBio Board since 2005. Hugh Martin remains the company’s

President and Chief Executive Officer.

Michael W. Hunkapiller, Ph.D., Executive Chairman, Pacific Biosciences (Photo: Business Wire)

“Mike has been a driving force in the sequencing industry for three

decades, and we are honored that he has agreed to take a more active

role with PacBio,” said Hugh Martin. “We look forward to being able to

draw more heavily on his expertise, experience and relationships with

customers in the life science tools market.”

Dr. Hunkapiller commented: “I have spent much of my career on the

leading edge of sequencing technology and I believe PacBio’s single

molecule, real-time technology will disrupt the sequencing market. I am

delighted that Hugh and the Board asked me to take on this newly created

role and look forward to devoting more time to advising the company on

how to accelerate adoption of their products in important applications.”

A renowned scientist, entrepreneur and life science industry executive,

Dr. Hunkapiller spent 21 years at Applied Biosystems (ABI), which he

co-founded and helped grow from startup to nearly $2 billion in annual

revenues supplying instrument and reagent systems for life science

research. He was also a founder of ABI’s sister company Celera Genomics

and Senior Vice President of Applera Corp. (their parent company). Prior

to joining ABI, Mike was a senior research fellow in the Division of

Biology at the California Institute of Technology.

For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.

You can also follow the company on twitter www.twitter.com/pacbio.

About Pacific Biosciences

Pacific Biosciences’ mission is to transform the way humankind acquires,

processes and interprets data from living systems through the design,

development and commercialization of innovative tools for biological

research. The company has developed a novel approach to studying the

synthesis and regulation of DNA, RNA and proteins. Combining recent

advances in nanofabrication, biochemistry, molecular biology, surface

chemistry and optics, Pacific Biosciences has created a powerful

technology platform called single molecule, real-time, or SMRT®,

technology. SMRT technology enables real-time analysis of biomolecules

with single molecule resolution, which has the potential to transform

the understanding of biological systems by providing a window into these

systems that has not previously been open for scientific study.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking

statements may contain words such as “believe,” “may,” “estimate,”

“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of

these terms, or other similar expressions, and include the assumptions

that underlie such statements. Such statements include, but are not

limited to, statements regarding the Company’s SMRT technology. These

statements are subject to known and unknown risks and uncertainties that

could cause actual results to differ materially from those expressed or

implied by such statements, including but not limited to risks discussed

from time to time in documents Pacific Biosciences of California, Inc.

has filed with the Securities and Exchange Commission, including the

risks identified under the section captioned “Risk Factors” in its

recently filed Quarterly Report on Form 10-Q. All forward-looking

statements are based on estimates, projections and assumptions as of the

date hereof. Pacific Biosciences undertakes no obligation to update any

forward-looking statements.

Photos/Multimedia Gallery Available: https://www.businesswire.com/cgi-bin/mmg.cgi?eid=50045971&lang=en

For Pacific BiosciencesNicole Litchfield, 415-793-6468 (Media)
nicole@bioscribe.com
or
Pacific

BiosciencesTrevin Rard, 650-521-8450 (Investors)
ir@pacificbiosciences.com

Source: Pacific Biosciences of California, Inc.

News Provided by Acquire Media

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.